
Please try another search
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Chaolin Zhang | - | 2020 | Member of Scientific Advisory Board |
Arthur O. Tzianabos | 62 | 2018 | Interim Executive Chairman |
Adrian R. Krainer | 65 | 2014 | Co-Founder & Independent Director |
Garry E. Menzel | 61 | 2020 | Independent Director |
Ian F. Smith | 59 | 2023 | Interim CEO & Director |
Jennifer C. Burstein | 53 | 2019 | Independent Director |
Arthur A. Levin | 71 | 2015 | Independent Director |
Seth L. Harrison | 65 | 2015 | Independent Director |
Julie Anne Smith | 54 | 2020 | Independent Director |
Edward M. Kaye | 76 | 2017 | Advisor & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review